Several Sector Leaders are struggling after clearing buy points, reflecting sideways action in the overall market recently. Salix Pharmaceuticals (SLXP) soared past a 141.91 flat-base buy point Aug. 19 on reports that the drugmaker could be a takeover target for Allergan (AGN), which is trying to fend off a takeover bid from Valeant Pharmaceuticals (VRX).